Phase 3 multicenter, randomized, double blind, placebo controlled, efficacy and safety study of Crenezumab in patients with prodromal to mild Alzheimer’s disease
This study is to determine if an experimental drug is effective in reducing the amount of amyloid plaque present in patients with mild Alzheimer’s disease.
Those eligible to participate in this study include:
Interactive Campus Map
2500 North State Street
Jackson, MS 39216
General Information: 601-984-1000
Patient Appointments: 888-815-2005